Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
Amgen has discontinued development of its eczema drug following disappointing Phase 3 trial results, raising concerns about the viability of new autoimmune therapies competing with Dupixent. This decision reflects ongoing challenges in the dermatology pipeline.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.